Senores Pharmaceuticals Reports Q1 FY27 Results; Revenue Hits ₹180 Cr as Management Strengthens Portfolio
Senores Pharmaceuticals Limited announced its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The company showcased strong growth across key business segments while continuing strategic investments derived from its Initial Public Offering (IPO).The company's consolidated revenue reached ₹180.21 crores in Q1 FY27. Overall performance reflected robust improvement in profitability and expanded operational focus in the regulated markets.
Consolidated Financial Overview
Unaudited consolidated financial results for the quarter ended June 30, 2026, presented alongside data from previous periods, show a diversified business structure spanning both regulated and emerging markets.Key highlights from the consolidated statement are summarized below:
| Particulars | For Quarter Ended June 30, 2026 | Quarter Ended March 31, 2026 | June 30, 2025 | Year Ended March 31, 2026 |
|---|---|---|---|---|
| Revenue From Operations (₹ in Crores) | 180.21 | 175.19 | 132.56 | 632.63 |
| Total Income (₹ in Crores) | 183.02 | 192.86 | 141.35 | 679.69 |
| Total Expenses (₹ in Crores) | 143.56 | 145.46 | 114.86 | 520.59 |
| Net Profit after Tax (₹ in Crores) | 30.45 | 36.67 | 21.18 | 121.53 |
Segmental Revenue Performance
The company operates across multiple segments, providing a detailed view of performance distribution:| Segment | Q1 FY27 Revenue (₹ crs) | Q1 FY26 Revenue (₹ crs) | Year-on-Year Growth |
|---|---|---|---|
| Regulated Markets | 127.8 | 90.1 | 41.9% |
| Emerging Markets | 37.6 | 29.0 | 29.6% |
| Branded Generics | 8.0 | 8.2 | -2.4% |
| Others | 6.8 | 5.2 | 29.2% |
| Total Revenue | 180.2 | 132.6 | 35.9% |
Key Operational and Strategic Developments
The Board of Directors approved the appointment of Ms. Anjali Shah, Assistant Vice President-Finance, as a Senior Management Personnel (SMP) effective July 27, 2026, following recommendations from the Nomination and Remuneration Committee.Regarding corporate funding, the company completed its Initial Public Offering (IPO) of 14,887,723 equity shares at an issue price of ₹391 per share, aggregating to ₹582.11 crores. Proceeds from the IPO have been utilized judiciously across various strategic objectives.
A summary of the utilization of IPO proceeds till June 30, 2026, is as follows:
| Item Head | Amount Proposed (₹ crs) | Amount Utilized (₹ crs) | Amount Unutilized (₹ crs) |
|---|---|---|---|
| Investment in Havix for manufacturing facility | 107.00 | 6.98 | 100.02 |
| Repayment/Pre-payment of borrowings | 73.10 | 73.10 | 0.00 |
| Investment in Havix for subsidiary borrowings | 20.20 | 20.20 | 0.00 |
| Funding working capital requirements | 43.26 | 43.26 | 0.00 |
| Investment in subsidiaries (Senores Pharma Inc. & Ratnatris Pharmaceuticals Pvt Ltd.) | 59.48 | 59.48 | 0.00 |
| Funding inorganic growth and strategic initiatives | 161.91 | 161.63 | 0.28 |
| Offer expenses | 35.04 | 34.80 | 0.24 |
| Total | 500.00 | 399.46 | 100.54 |
Management Commentary and Outlook
Commenting on the quarter's performance, Mr. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, noted that the company delivered a healthy performance in Q1 FY27 despite a challenging operating environment. He highlighted that the Regulated Markets business registered robust revenue growth of 42% year-over-year.Mr. Shah emphasized continuous operational excellence, noting that the addition of a USFDA approved manufacturing plant enhances scalability and accelerates product launches. He stated that the Emerging Markets business is on a steady trajectory, with EBITDA Margin near mid teens, and it has become cash flow positive. The company maintains a strong foundation backed by its differentiated product portfolio and a clear growth roadmap, signaling confidence in sustaining momentum throughout FY27 and beyond.
SENORES Stock Price Movement
Today, shares of Senores Pharmaceuticals Limited gained 0.58% after the market closed, settling at ₹1412. The stock traded within an intraday range of ₹1378 to ₹1443.7, with a volume of 422,207 recorded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.